From Polyphenols to Prodrugs: Bridging the Blood–Brain Barrier with Nanomedicine and Neurotherapeutics
Open accessThe DOI matches its Crossref record; 685 of the 685 references it cites were found in a registry or an index.
Abstract
Central nervous system disorders drive disability, yet many neuroactive candidates fail because the brain is a hard compartment to dose. Plant-derived molecules spanning polyphenols, alkaloids, terpenoids, and cannabinoids are attractive because their pleiotropic actions can engage oxidative stress, neuroinflammation, and circuit dysfunction. In practice, the blood–brain barrier (BBB) restricts most native phytochemicals through tight-junction selectivity, rapid metabolism, low solubility, and transporter-mediated efflux. Key gaps include poor standardization of exposure metrics, limited human-relevant BBB models, and few head-to-head studies that compare delivery platforms on the same payload and outcome. This review tackles the mismatch between mechanistic promise and reliable brain exposure that stalls translation. The objectives are to link phytochemical liabilities to enabling strategies in nanomedicine, alternative routes, and transporter-targeted prodrugs, and to propose decision-grade endpoints for translation. We synthesize evidence on BBB transport logic, nanocarrier families, targeting ligands, intranasal delivery, focused ultrasound-mediated opening, and prodrug approaches that hijack influx transporters, while foregrounding safety and chemistry, manufacturing, and controls (CMC) constraints. Here we highlight that effective neurotherapeutics emerge when chemistry, carrier, route, and measurement are co-designed rather than optimized in isolation. This framework can guide platform selection, de-risk first in-human studies, and sharpen trial endpoints. More broadly, it offers a transferable playbook for barrier-limited drug development across neurology, psychiatry, and oncology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Nevertheless, BBB constraints remain a central translational hurdle [126].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [126]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 601–685 of 685
Suriyaamporn, P., Kansom, T., Pamornpathomkul, B., Ngawhirunpat, T., Opanasopit, P., & Ramjan, S. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.126080 · Cited by 14
Kim, J. S., Lee, D. H., Seo, H. K., Lee, H., Kim, G., Nie, C. X., Hong, Y., Yoon, Y., Lim, J., Park, S. J., et al. (2025) · Small · doi:10.1002/smll.202506162 · Cited by 14
From Biomarkers to Behavior: Mapping the Neuroimmune Web of Pain, Mood, and Memory
Tanaka, M., & Battaglia, S. (2025) · Biomedicines · doi:10.3390/biomedicines13092226 · Cited by 13
Self-citationBiomarkers of Neuroinflammation in Traumatic Brain Injury
Gerber, K. S., Alvarez, G., Alamian, A., Behar‐Zusman, V., & Downs, C. A. (2022) · Clinical Nursing Research · doi:10.1177/10547738221107081 · Cited by 13
Adscheid, S. A., Rojas‐Rodríguez, M., Abdel-Hafez, S. M., Pavone, F. S., Schneider, M., Türeli, A. E., Calamai, M., & Günday-Türeli, N. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17010087 · Cited by 13
Benita, B. A., & Koss, K. M. (2024) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2024.1443985 · Cited by 13
Glader, C., Jeitler, R., Wang, Y., van Tuijn, R., Grau‐Carbonell, A., Tetyczka, C., Mesite, S., Caisse, P., Khinast, J., & Roblegg, E. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17060684 · Cited by 13
Martos, D., Lőrinczi, B., Szatmári, I., Vécsei, L., & Tanaka, M. (2025) · doi:10.20944/preprints202504.1511.v2 · Cited by 13
Self-citationMartos, D., Lőrinczi, B., Szatmári, I., Vécsei, L., & Tanaka, M. (2025) · Cells · doi:10.3390/cells14130973 · Cited by 12
Self-citationSoricellis, C. D., Amante, C., Russo, P., Aquino, R. P., & Gaudio, P. D. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17010129 · Cited by 12
Neurological effects of carbon quantum dots on zebrafish: A review
Sharma, M., Kumar, C., Arya, S. K., Puri, S., & Khatri, M. (2024) · Neuroscience · doi:10.1016/j.neuroscience.2024.10.016 · Cited by 12
Nozohouri, E., Noorani, B., Patel, D., Ahn, Y., Zoubi, S., & Bickel, U. (2025) · Fluids and Barriers of the CNS · doi:10.1186/s12987-025-00685-2 · Cited by 12
Etukudo, E. M., Usman, I. M., Oviosun, A., Ojiakor, V. O., Makena, W., Owembabazi, E., Aja, P. M., Vivalya, B. M. N., Archibong, V. B., & Anyanwu, G. E. (2025) · Journal of Experimental Pharmacology · doi:10.2147/jep.s536765 · Cited by 12
Neurogenesis and Neuroinflammation in Dialogue: Mapping Gaps, Modulating Microglia, Rewiring Aging
Tanaka, M. (2026) · Cells · doi:10.3390/cells15010078 · Cited by 11
Self-citationDualistic Dynamics in Neuropsychiatry: From Monoaminergic Modulators to Multiscale Biomarker Maps
Tanaka, M., & Battaglia, S. (2025) · Biomedicines · doi:10.3390/biomedicines13061456 · Cited by 11
Self-citationScreening extemporaneously compounded intraspinal injections with the bacterial endotoxins test
Cooper, J. F., & Thoma, L. A. (2002) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/59.24.2426 · Cited by 11
Biomarkers as Endpoints in Clinical Trials for Alzheimer’s Disease
Elghanam, Y., Purja, S., & Kim, E. Y. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240008 · Cited by 11
Filieri, S., Miciaccia, M., Armenise, D., Baldelli, O. M., Liturri, A., Ferorelli, S., Sardanelli, A. M., Perrone, M. G., & Scilimati, A. (2025) · Pharmaceuticals · doi:10.3390/ph18040525 · Cited by 11
Smart liposomal systems for brain cancer: Technological innovations in drug delivery
Zuberi, A., Rehman, U., Gupta, G., Ghazwani, M., Hani, U., & Kesharwani, P. (2025) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2025.114904 · Cited by 11
Blood-brain barriers and drug pharmacokinetics: mechanisms and models
Tregub, P. P., Bystrov, D. A., Kushnir, I. A., Korsakova, S. A., Yurchenko, S. O., & Salmina, A. B. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177872 · Cited by 11
Hugele, A., Löffler, S., Molina, B., Guillon, M., Montaser, A., Auriola, S., & Huttunen, K. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1034964 · Cited by 10
Improving drug delivery to the brain: the prodrug approach
Huttunen, K. M. (2024) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2024.2355180 · Cited by 10
PEGylated liposomes via ATRP for brain drug delivery
Chen, L., Zhang, Z., Simonsen, M. R., Owens, T., Khorooshi, R., & Wu, C. (2025) · Journal of Liposome Research · doi:10.1080/08982104.2025.2485428 · Cited by 10
Self-Assembled systems for Nose-to-Brain delivery of Temozolamide (TMZ) in brain tumor therapy
Bhagat, N., Nalawala, Z., Patel, J., Das, D., Baldha, R., Sarolia, J., & Rathod, S. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.125540 · Cited by 10
Dirir, A. M., Ali, A. H., & Hachem, M. (2025) · International Journal of Nanomedicine · doi:10.2147/ijn.s537566 · Cited by 10
Ma, W., Li, Y., Lu, Y., Liang, Z., Yu, H., Han, J., Liu, J., Wang, W., Peng, C., & Cheng, J. (2025) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s456712 · Cited by 10
Juhász, L., Galla, Z., Tanaka, M., & Vécsei, L. (2026) · Antioxidants · doi:10.3390/antiox15020261 · Cited by 10
Self-citationRole of Transporters and Enzymes in Metabolism and Distribution of 4-Chlorokynurenine (AV-101)
Patel, W., Shankar, R. G., Smith, M. A., Snodgrass, H. R., Pirmohamed, M., Jorgensen, A., Alfirevic, A., & Dickens, D. (2024) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.3c00700 · Cited by 9
Văruț, R. M., Popescu, A. I. S., Găman, S., Niculescu, C. E., Niculescu, Ș. A., Dop, D., Stepan, M. D., Ionovici, N., Singer, C. E., & Popescu, C. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17030355 · Cited by 9
Mu, R., Liu, T.-L., Liu, X., & Liu, L. C. (2024) · Acta Pharmacologica Sinica · doi:10.1038/s41401-024-01255-2 · Cited by 9
Mathew, S., Oerter, S., Reitenbach, E., Gätzner, S., Höchner, A., Jahnke, H., Piontek, J., Neuhaus, W., Brachner, A., Metzger, M., et al. (2025) · Advanced Biology · doi:10.1002/adbi.202400442 · Cited by 9
Xu, G., Ma, C., Chu, H., Hu, W., Yang, L., & Li, S. (2025) · International Journal of Nanomedicine · doi:10.2147/ijn.s508800 · Cited by 9
Qiu, Y., Jacobs, D. M., Messer, K. S., Salmon, D. P., Wellington, C. L., Stukas, S. K., Revta, C., Brewer, J. B., Léger, G. C., Askew, B., et al. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01745-3 · Cited by 9
Pan, F., Xia, Y., Zhang, B., Mohammed, A., & Zhao, X. (2025) · Langmuir · doi:10.1021/acs.langmuir.5c02318 · Cited by 9
Chehadi, A. C., Pereira de Lima, E., Detregiachi, C. R. P., Santos de Argollo Haber, R., Catharin, V. M. C. S., Fornari Laurindo, L., Engracia Valenti, V., Machado Galhardi, C., Tanaka, M., & Maria Barbalho, S. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27010465 · Cited by 8
Self-citationSpecial Issue “Translating Molecular Psychiatry: From Biomarkers to Personalized Therapies”
Tanaka, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262010238 · Cited by 8
Self-citationMishra, A., Payne, C., Carrascal-Miniño, A., Sunassee, K., Halbherr, S., Pouliopoulos, A. N., & de Rosales, R. T. M. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114183 · Cited by 8
Fu, L., Bridges, C. A., Kim, H. N., Ding, C., Hou, N. C. B., Yeow, J., Fok, S., Macmillan, A., Sterling, J. D., Baker, S., et al. (2024) · Biomacromolecules · doi:10.1021/acs.biomac.4c00477 · Cited by 8
Gülave, B., van den Maagdenberg, H. W., van Boven, L., van Westen, G. J. P., de Lange, E. C. M., & van Hasselt, J. G. C. (2025) · Pharmaceutical Research · doi:10.1007/s11095-025-03828-0 · Cited by 8
Wickramasinghe, C. D., Kim, S., & Li, J. (2025) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.70026 · Cited by 8
Cui, L., Perini, G., Minopoli, A., Palmieri, V., Spirito, M. D., & Papi, M. (2025) · International Journal of Pharmaceutics X · doi:10.1016/j.ijpx.2025.100349 · Cited by 8
Upadhyay, G., Fihurka, O., Patel, P., & Sanchez‐Ramos, J. (2025) · Journal of Cannabis Research · doi:10.1186/s42238-025-00308-5 · Cited by 8
Kühn, P., Petralla, S., Dabbagh, F., Pegoretti, V., Muranyi, W., Ishikawa, H., Schroten, H., Fischer, R., Frenzel, A., Schirrmann, T., et al. (2025) · mAbs · doi:10.1080/19420862.2025.2563758 · Cited by 8
Bowman, C. M., Ma, F., Mao, J., Plise, E. G., Chen, E., Liu, L., Zhang, S., & Chen, Y. (2023) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.2344 · Cited by 7
Plasma membrane damage limits cytoplasmic delivery by conventional cell penetrating peptides
Polderdijk, S. G. I., Limzerwala, J. F., & Spiess, C. (2024) · PLoS ONE · doi:10.1371/journal.pone.0305848 · Cited by 7
Biological testing unification for hemodialysis membranes evaluation: A step towards standardization
Tienda-Vázquez, M. A., Arredondo, P., Mejía-Delgadillo, X., Rodríguez‐González, J. A., Soto-Cajiga, J. A., Sabath, E., Lozano, O., & Almanza-Arjona, Y. C. (2025) · Biomaterials Advances · doi:10.1016/j.bioadv.2024.214165 · Cited by 7
Wu, Y., Chen, Z., Chen, F., Su, J., Han, J., & Liu, S. (2025) · Analytical Chemistry · doi:10.1021/acs.analchem.5c00365 · Cited by 7
Zou, L., Chien, H., Pade, D., Li, Y., Nguyen, M., Bhamidipati, R. K., Wang, Z., Enogieru, O. J., & Wahlstrom, J. L. (2025) · The AAPS Journal · doi:10.1208/s12248-025-01035-8 · Cited by 7
Shen, C., Yang, M., Hsieh, W.-Y., Tsay, G. J., Yang, Y., Huang, Y., Liu, S.-Y., Lai, C.-M., Lee, C. H., Tang, C., et al. (2025) · ACS Nanoscience Au · doi:10.1021/acsnanoscienceau.5c00004 · Cited by 7
Zhang, Y., Guo, Z., Zhang, H., Wei, H., Wang, T., Du, S., & Li, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26083861 · Cited by 7
Functional Self-Immolative Hydrogels with Dendritic Cross-Linkers for Controlled Drug Delivery
Muñoz-Sánchez, S., Gong, J., de la Mata, F. J., Gillies, E. R., & García‐Gallego, S. (2025) · Chemistry of Materials · doi:10.1021/acs.chemmater.5c01006 · Cited by 7
Szabó, Á., Galla, Z., Spekker, E., Martos, D., Szűcs, M., Fejes-Szabó, A., Fehér, Á., Takeda, K., Ozaki, K., Inoue, H., et al. (2025) · Cells · doi:10.3390/cells14211711 · Cited by 7
Self-citationBravo‐Ferrer, I., Gaasdal-Bech, K., Colvin, C., Vaughan, H. J., Moss, J., Williams, A., & Castro, B. D. (2025) · Brain Communications · doi:10.1093/braincomms/fcaf332 · Cited by 7
Szabó, Á., Galla, Z., Spekker, E., et al. (2025) · Preprints.org · doi:10.20944/preprints202510.0580.v2 · Cited by 6
Petersen, R. C., Graf, A., Brady, C., Santi, S. D., Florian, H., Landen, J. W., Pontecorvo, M., RANDOLPH, C. C., Sink, K. M., Carrillo, M. C., et al. (2025) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.70038 · Cited by 5
Yang, H., Liu, R., Huang, J., Zhao, Y., Zou, C.-L., Wu, D.-L., & Zhao, H. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.146761 · Cited by 5
Ligand and Structure-based Modeling of Passive Diffusion through the Blood-Brain Barrier
Vilar, S., Sobarzo‐Sánchez, E., Santana, L., & Uriarte, E. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867324666171106163742 · Cited by 5
Affibody Molecules Intended for Receptor-Mediated Transcytosis via the Transferrin Receptor
Hjelm, L., Lindberg, H., Ståhl, S., & Löfblom, J. (2023) · Pharmaceuticals · doi:10.3390/ph16070956 · Cited by 5
Thiberville, L., Faivre, V., Sizun, C., Dehouck, M., Landry, C., Baati, R., & Tsapis, N. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.125505 · Cited by 5
Kang, H. J., Roh, J., Lee, H., Park, E. M., Lee, H. W., Lee, J. Y., Hwang, J. H., Shim, J., & Choi, K. (2025) · Annals of Laboratory Medicine · doi:10.3343/alm.2024.0443 · Cited by 5
Ling, C., Chen, L., Liang, J., Li, X., Wei, H., Yu, C., & Wang, J. (2025) · Materials Today Bio · doi:10.1016/j.mtbio.2025.102077 · Cited by 5
Sundheimer, J. K., Benzel, J., Longuespée, R., Burhenne, J., Pfister, S. M., Maaß, K. K., Sauter, M., & Pajtler, K. W. (2025) · Clinical and Translational Science · doi:10.1111/cts.70226 · Cited by 5
Sharma, S., Lee, D., Maity, S., Singh, P., Chadokiya, J., Mohaghegh, N., Najafabadi, A. H., Kim, H., Gangrade, A., Ljubimova, J. Y., et al. (2025) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.5c00168 · Cited by 5
Morozova, V., Pellegata, D., Singer, S. A., Charles, R., Müller, J., Altmann, K., & Gertsch, J. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118402 · Cited by 5
Ebert, A., & Goss, K. (2025) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2025.107354 · Cited by 5
Ali, S., Ali, S. A., Kumar, M., Jahan, I., & Hak, J. (2025) · Current Pharmaceutical Research · doi:10.63785/cpr.2025.1.1.114 · Cited by 5
Juhász, L., Galla, Z., Tanaka, M., & Vécsei, L. (2026) · doi:10.20944/preprints202601.0822.v1 · Cited by 5
Self-citationCharacteristics of Trials Preceding FDA Approval of Novel Psychiatric Drugs
Ahn-Horst, R. Y., Turner, E. H., & Kesselheim, A. S. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.56588 · Cited by 4
Evaluating critical quality attributes and novel drug release testing of difluprednate nanoemulsions
Palakurthi, S. S., Charbe, N. B., Kapre, S., Zheng, W., Thalla, M., Palaniappan, D., Lu, D., & Palakurthi, S. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.125431 · Cited by 4
Molecular determinants of neuroprotection in blood-brain interfaces of the cynomolgus monkey
Strazielle, N., Blondel, S., Confais, J., Khoury, R. E., Contamin, H., & Ghersi‐Egea, J. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1523819 · Cited by 4
ACTR-23. SAFETY OF INTRA-ARTERIAL CHEMOTHERAPY WITH OSMOTIC OPENING OF THE BLOOD-BRAIN BARRIER
Priest, R. A., Ambady, P., & Neweult, E. (2018) · Neuro-Oncology · doi:10.1093/neuonc/noy148.057 · Cited by 4
Hugon, G., Goutal, S., Dauba, A., Breuil, L., Winkeler, A., Novell, A., & Tournier, N. (2021) · Research Square · doi:10.21203/rs.3.rs-693599/v1 · Cited by 4
Rotamer-Controlled Self-Immolative Linkers Enable Tunable Release of Neurosteroid Oxime Prodrugs
van der Westhuyzen, A. E., Hodson, L. E., Pashikanti, G., Fritzemeier, R. G., Yeung, S. B., Mancia, A., Lian, D. R., Tholath, P. J., Paez, A. C., Chavan, L. N., et al. (2025) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.5c00452 · Cited by 3
Lai, W.-Y., Chuang, C.-W., Huang, Y.-C., & Huang, C. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107795 · Cited by 3
Identification of Variable Lymphocyte Receptors That Target the Human Blood–Brain Barrier
Katt, M. E., Waters, E. A., Gastfriend, B. D., Herrin, B. R., Cooper, M. D., & Shusta, E. V. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17091179 · Cited by 3
Secrétan, P.-H., Annereau, M., & Do, B. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17091202 · Cited by 3
Ratcliffe, L., Vermond, S., Hill, S., de Munnik, S., van Puijvelde, G., Quist, B., Pooley, R., Carr, K. A., Brown, N., Aspinall-O’Dea, M., et al. (2025) · Cancer Research · doi:10.1158/1538-7445.am2025-lb009 · Cited by 3
From Monoamines to Systems Psychiatry: Rewiring Depression Science and Care (1960s–2025)Preprint
Tanaka, M. (2025) · Preprints.org · doi:10.20944/preprints202512.0290.v2 · Cited by 3
Self-citationPa, C., Shen, S., Dai, Y. L., & Wu, M. (2025) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2025.1614132 · Cited by 2
Screen, Sample, Stratify: Biomarkers and Machine Learning Compress Dementia Pathways
Battaglia, S., & Tanaka, M. (2026) · Biomedicines · doi:10.3390/biomedicines14010159 · Cited by 2
Self-citationPredicting the Brain-To-Plasma Unbound Partition Coefficient of Compounds via Formula-Guided Network
Zou, Y., Yuan, H., Guo, Z., Guo, T., Fu, Z., Wang, R., Xu, D., Wang, Q., Wang, T., & Chen, L. (2025) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5c00590 · Cited by 2
EXTH-66. NEO100 TRANSIENTLY OPENS UP THE BLOOD BRAIN BARRIER VIA TIGHT JUNCTION INHIBITION
Chen, T., Wang, W., Marín‐Ramos, N. I., & Schönthal, A. H. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa215.420 · Cited by 1
Endo, H., Ogasawara, M., Tega, Y., Kubo, Y., Hosoya, K., & Akanuma, S. (2024) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b24-00481 · Cited by 1
Red Blood Cell-Derived Particles Induce Endothelial Damage Via the Alternative Complement Pathway
Nguyen, K., Meuleman, M.-S., Bodivit, G., Kassasseya, C., Decrouy, X., Vingert, B., Bencheikh, L., Lambris, J. D., Pirenne, F., Roumenina, L. T., et al. (2024) · Blood · doi:10.1182/blood-2024-207164 · Cited by 1
Cited by
Dietary Polyphenols in Brain Aging: Molecular Mechanisms and Implications for Neurodegeneration
Mózes, N., Varga, J. T., Szwajgier, D., Kryczyk‐Poprawa, A., Zábó, V., Lehoczki, A., Lipécz, Á., Csípő, T., Fazekas‐Pongor, V., Major, D., et al. (2026) · Nutrients · doi:10.3390/nu18091470 · Cited by 5
“Certain low-molecular-weight polyphenols, particularly flavonoid aglycones, may cross the BBB via passive diffusion or transporter-mediated mechanisms, although evidence in humans remains limited [139].”
Li, Y., Luo, R., Li, Y., Liu, Z., Duan, X., Qin, S., He, Z., & Liu, S. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119888 · Cited by 3
Zamani, N. I. S. M., Hamezah, H. S., Mediani, A., Ghazali, M., Sadikan, M. Z., & Jam, F. A. (2026) · Scientific Reports · doi:10.1038/s41598-026-53311-y · Cited by 2
“To overcome these limitations, nanoparticle-based delivery systems have been widely explored to enhance brain targeting and improve central nervous system (CNS) bioavailability of polyphenolic compounds 51 .”
Dakanalis, A., Papadopoulou, S. Κ., Mentzelou, M., Migdanis, A., Migdanis, I., & Giaginis, C. (2026) · Nutrients · doi:10.3390/nu18142362 · Cited by 3
Uti, D. E., Alum, E. U., Okpe, J. M., Egbung, J. E., & Mbah, J. O. (2026) · Tissue and Cell · doi:10.1016/j.tice.2026.103524 · Cited by 1
Metadata
- Authors
- Tanaka, M., Araujo, A. C., Valenti, V. E., Guiguer, E. L., Catharin, V. C. S., Gualhardi, C. M., de Souza Bastos Mazuqueli Pereira, E., de Alvares Goulart, R., de Argolo Haber, R. S., de Carvalho, A. C. A., & Barbalho, S. M.
- Affiliations
- University of Szeged (HU)
- Department of Biochemistry and Pharmacology, School of Medicine, Faculdade de Medicina de Marília, Universidade de Marília (UNIMAR), Marilia 17525-902, SP, Brazil
- Universidade Estadual Paulista (Unesp) (BR)
- Graduate Program in Structural and Functional Interactions in Rehabilitation, School of Medicine, Universidade de Marília (UNIMAR), Marilia 17525-902, SP, Brazil
- Corresponding author
- Tanaka, Masaru
- Barbalho, Sandra Maria
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2026-03-03
- Volume
- 27
- Issue
- 5
- Pages
- 2370
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC12985693
- OpenAlex
- W7133487442
- Cited by
- 13
- References
- 654
- Citations by year
- 2026: 13
- FWCI
- 9.92
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- Preprints.org (acceptedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- HUN-REN Hungarian Research Network (-)
- Topics
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Keywords
- blood-brain barrier, polyphenols, prodrugs, phytochemicals, nanocarriers, neurotherapeutics, intranasal drug delivery, focused ultrasound, BBB transporters, tight junctions, brain exposure, drug delivery routes, neuroinflammation, oxidative stress
- MeSH terms
- Animals, Blood-Brain Barrier, Central Nervous System Diseases, Humans, Prodrugs, Drug Delivery Systems, Nanomedicine, Polyphenols
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.